

1                   Metabolomics strategy for diagnosing urinary tract infections

2   Daniel B. Gregson<sup>1,2†</sup>, Spencer D. Wildman<sup>3†</sup>, Carly C.Y. Chan<sup>3†</sup>, Dominique G. Bihan<sup>3</sup>, Ryan  
3   A. Groves<sup>3</sup>, Raied Aburashed<sup>3</sup> Thomas Rydzak<sup>3</sup>, Keir Pittman<sup>3</sup>, Nicolas Van Bavel<sup>3</sup>, and Ian A.  
4   Lewis<sup>3\*</sup>

5   <sup>1</sup> Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University  
6   of Calgary, Calgary, AB, T2N 1N4, Canada

7   <sup>2</sup> Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,  
8   T2N 1N4, Canada

9   <sup>3</sup> Alberta Centre for Advanced Diagnostics, Department of Biological Science, University of  
10   Calgary, Calgary, AB, T2N 1N4, Canada

11

12   † Equal contributions

13   \*Corresponding author: Ian A. Lewis

14   Department of Biological Sciences  
15   2500 University Drive NW  
16   Calgary, AB, Canada T2N 1N4  
17   1-403-220-4366  
18   ian.lewis2@ucalgary.ca

19

20

21

22

23

24

25

26 **Abstract**

27 Metabolomics has emerged as a mainstream approach for investigating complex metabolic  
28 phenotypes but has yet to be integrated into routine clinical diagnostics. Metabolomics-based  
29 diagnosis of urinary tract infections (UTIs) is a logical application of this technology since  
30 microbial waste products are concentrated in the bladder and thus could be suitable markers of  
31 infection. We conducted an untargeted metabolomics screen of clinical specimens from patients  
32 with suspected UTIs and identified two metabolites, agmatine and N6-methyladenine, that are  
33 predictive of culture positive samples. We developed a 3.2-minute LC-MS assay to quantify these  
34 metabolites and showed that agmatine and N6-methyladenine correctly identify UTIs caused by 13  
35 *Enterobacterales* species and 3 non-*Enterobacterales* species, accounting for over 90% of  
36 infections (agmatine AUC > 0.95; N6-methyladenine AUC > 0.89). These markers were robust  
37 predictors across two blinded cohorts totaling 1,629 patient samples. These findings demonstrate  
38 the potential utility of metabolomics in clinical diagnostics for rapidly detecting UTIs.

39

40

41

42

43

44

45

46

47

48

49

50

51

52 **Main Text**

53 **Introduction**

54 Infections are caused by a wide range of microbes that, like all organisms, consume nutrients  
55 and secrete metabolic waste products. These microbial metabolites can be highly abundant at the  
56 site of infection<sup>1</sup> and thus, could potentially serve as targets for a metabolism-based diagnostic  
57 strategy. Urinary tract infections (UTIs) are particularly amenable to this metabolic diagnostic  
58 approach because microbial metabolites are concentrated in the bladder and can be easily detected  
59 by liquid chromatography mass spectrometry (LC-MS) analysis of patient urine. *Escherichia coli*,  
60 the most common UTI pathogen, produces a variety of diamines, polyamines, and acylated  
61 conjugates of these molecules that are not typically found in human urine. These molecules have  
62 been reported as potential UTI biomarkers for over three decades<sup>2,3</sup>, with more recent work  
63 suggesting that these amine-linked molecules may play a role in resistance to nitrosative stress in  
64 the bladder<sup>4,5</sup>.

65 Although microbial metabolites have been recognized as potential diagnostic targets, they have  
66 yet to be translated into a clinical diagnostic tool. The reason for this is threefold: 1) concentrations  
67 of the microbial polyamines are quite variable in urine<sup>6</sup> and are thus of borderline utility for  
68 diagnostic purposes, 2) only biomarkers of *E. coli* have been reported thus far, which is problematic  
69 because it is only one of many UTI-causing organisms<sup>7</sup>, and 3) LC-MS has only recently become  
70 sufficiently robust to serve as a practical diagnostic platform. The primary objective of this study  
71 was to conduct a systematic analysis of microbial metabolites found in urine from symptomatic  
72 UTI patients to identify any molecules with sufficient predictive power to enable rapid, metabolic-  
73 based diagnostics. Using an untargeted LC-MS metabolomics approach, we identified two novel  
74 biomarkers that report on a wide transect of UTI pathogens. We then assess the potential utility of  
75 metabolomics-based UTI screening in two blinded cohorts totaling 1,629 urine samples.

## 76 **Results**

### 77 *UTI biomarker discovery*

78 UTIs are diagnosed based on patient symptoms supported by laboratory diagnostic tests. These  
79 clinical tests include culturing urine specimens for 18 hours to identify patients with significant  
80 bacteriuria (defined by Alberta Precision Laboratories guidelines as specimens with  $>10^7$  CFU/L)<sup>8</sup>.  
81 Microbial catabolites present in the urine could potentially provide a culture-independent  
82 mechanism for rapidly identifying these positive samples. To identify potential biomarkers in these  
83 urine specimens, untargeted metabolomics analyses (Figure 1a; Supporting Dataset 1) of 77  
84 culture-positive urine samples and 33 culture negative samples ( $<10^7$  CFU/L)—all collected from  
85 symptomatic patients—were conducted using LC-MS. The most diagnostic features in this dataset,  
86 as judged by area under the curve (AUC) of the receiver operating characteristic (ROC) curve, were  
87 m/z 114.1025 (AUC=0.98), m/z 131.1289 (AUC=0.89), and m/z 150.0772 (AUC= 0.91; Figure 1b;  
88 Supporting Dataset 1). The first two of these untargeted signals were putatively assigned to  
89 agmatine, a product of arginine metabolism<sup>9</sup>, and the third was assigned to N6-methyladenine, a  
90 modified nucleobase found in prokaryotes<sup>10</sup>. These assignments were validated by LC-MS/MS  
91 fragmentation patterns as well as co-elution of the target signal with analytical standards (Figure  
92 1c,d).

### 93 *Validation of agmatine as a UTI biomarker*

94 Although both agmatine and N6-methyladenine were predictive of positive urine cultures, the  
95 levels of these metabolites were not uniform across UTI-causing pathogens. Infections caused by  
96 the most prominent UTI-causing *Enterobacterales* species, such as *E. coli*, were associated with  
97 elevated agmatine, whereas N6-methyladenine levels were elevated in infections caused by a small  
98 number of non-*Enterobacterales* species (Supporting Dataset 1). To better understand these  
99 species-specific phenotypes, the performance of agmatine was assessed using 519 urine cultures  
100 that were taken directly from a clinical diagnostic pipeline. Stable isotope labeled [U-<sup>13</sup>C]agmatine

101 was spiked into samples, samples were purified using solid phase extraction (SPE) on a silica  
102 column, and agmatine and [U-<sup>13</sup>C]agmatine levels were measured using a targeted mass  
103 spectrometry method. Agmatine concentrations were thus quantifiable based on the signal ratio  
104 between isotope-labeled and native species. As expected, urinary agmatine levels were closely  
105 correlated with the presence of uropathogenic *Enterobacteriales*, whereas culture-negative urine  
106 samples contained no detectable agmatine (AUC of 0.99, CI of 0.98 - 1.00; Fig 2a; Supporting  
107 Dataset 2). Moreover, we found that a diagnostic threshold of 174 nM agmatine was predictive of  
108 infections caused by *E. coli*, *Citrobacter* species, *Enterobacter* species, *Klebsiella* species, and  
109 *Proteus mirabilis* (sensitivity, 94%; specificity, 97%; PPV, 0.96; NPV, 0.95; Figure 2a), all of  
110 which showed significantly higher agmatine levels than urine from culture negative patients ( $p =$   
111  $2.15 \times 10^{-45}$ ,  $p = 1.43 \times 10^{-49}$ ,  $p = 2.22 \times 10^{-52}$ ,  $p = 3.85 \times 10^{-40}$ ,  $p = 5.91 \times 10^{-47}$ , respectively via two-tail  
112 unequal variance Welch T-test relative to culture negative urine samples; Supporting Dataset 2).

### 113 *Validation of N6-methyladenine as a UTI biomarker*

114 Although the agmatine-based screening approach captures most UTI infections caused by  
115 *Enterobacteriales* species—which collectively account for >83% of UTIs<sup>7</sup>—it did not capture those  
116 caused by enterococci, staphylococci, or other less common species (e.g Group B strep,  
117 *Pseudomonas aeruginosa*, *Aerococcus urinae*, *Candida albicans*). Since these pathogens account  
118 for a small percentage of all UTIs, we prospectively collected a targeted cohort of 71 non-  
119 *Enterobacteriales* UTI specimens along with 24 negative controls. LC-MS analyses showed that  
120 N6-methyladenine signals correctly differentiated culture-negative urine samples from this selected  
121 cohort of infections (sensitivity, 91%; specificity, 83%; PPV, 0.84; NPV, 0.91; Figure 2b;  
122 Supporting Dataset 3). However, there were clear species-to-species differences in the quality of  
123 these metabolic diagnostics, with *Staphylococcus aureus*, *Staphylococcus saprophyticus*, and  
124 *Aerococcus urinae* showing the most significant differences after Bonferroni correction from  
125 multiple hypothesis testing ( $p = 1.26 \times 10^{-3}$ ,  $p = 3.22 \times 10^{-4}$ ,  $p = 3.72 \times 10^{-6}$ , respectively via two-tail

126 unequal variance Welch T-test relative to culture negative urine samples; Figure 2b; Supporting  
127 Dataset 4). N6-methyladenine levels were predictive of these three non-*Enterobacterales* species  
128 (AUC of 0.80; CI, 0.69 – 0.92; Supporting Dataset 3). N6-methyladenine is part of a wider family  
129 of adenine derivatives, including 1-methyladenine and adenine, which were elevated in the urine  
130 of these UTI patients (Supporting Dataset 4). However, our LC-MS analyses showed that the  
131 diagnostic performance of these additional markers was lower, and these compounds were linked  
132 to fewer species than N6-methyladenine.

### 133 *Validation of microbial metabolic capacity*

134 Agmatine and N6-methyladenine in the urine of UTI patients could potentially originate from  
135 microbial or human metabolism. To better understand the origin of these molecules, filter sterilized  
136 urine was taken from healthy controls and was inoculated with *E. coli* and *S. aureus* isolates. In the  
137 case of the *E. coli* culture, 20  $\mu\text{M}$  of  $^{15}\text{N}$ -labelled arginine (a physiologically relevant level  
138 approximating the concentration of native urinary arginine) was added to the urine at the start of  
139 the incubation. Throughout the incubation, isotope-labeled arginine levels progressively decreased  
140 while isotope-labeled agmatine was produced (Figure 2c). The appearance of isotope-labeled  
141 agmatine is expected under these conditions due to the microbial arginine decarboxylase activity  
142 of *E. coli*<sup>9</sup>. Likewise, we screened the *S. aureus* cultures over 12 hours via LC-MS and observed  
143 that N6-methyladenine was produced by these microbes when grown in filter-sterilized urine  
144 (Figure 2c). In summary, the most diagnostic biomarkers observed in UTI specimens are readily  
145 produced by UTI pathogens grown in filter-sterilized urine, indicating that these metabolites are  
146 naturally produced through microbial metabolic activity.

147 Urine specimens for UTI diagnostics are generally collected in outpatient clinics and delivered  
148 to centralized microbiology testing labs. Sample transport logistics and other delays in analysis  
149 could therefore complicate microbial diagnostics if microbes were allowed to grow. To control this,  
150 urine specimens are collected in boric acid tubes, which inhibit microbial growth. To verify that

151 microbes stored in boric acid tubes will not produce our target metabolites, which could cause false  
152 positive results in specimens with sub-clinical bacterial levels ( $< 10^7$  CFU/L), we screened for  
153 agmatine production in three reference strains of *E. coli* and four clinical isolates, in boric acid over  
154 24 hours via LC-MS. In the absence of boric acid preservatives, agmatine levels reached a peak  
155 intensity after 7 hours and maintained elevated levels over the next 17 hours (Supplementary Figure  
156 1a). In contrast, isolates stored in boric acid preservatives did not produce agmatine over the 24-  
157 hour period (Supplementary Figure 1b).

### 158 *Clinical Cohort 1*

159 Although untargeted metabolomics is currently not used for clinical diagnostics, mass  
160 spectrometry is a routine component of many diagnostic labs where it serves as a platform for  
161 quantifying a range of biomolecules including steroid hormones, drugs of abuse, and metabolites  
162 that are linked to inborn errors of metabolism<sup>11</sup>. Consequently, much of the requisite infrastructure  
163 necessary for diagnosing UTIs via metabolic profiles can be found in diagnostic laboratories.  
164 However, the instrumentation used for untargeted metabolomics analyses is quite different from  
165 that employed in clinical settings. To demonstrate the feasibility of adapting our metabolomics  
166 approach to routine clinical diagnostics, we developed a targeted diagnostics workflow using a  
167 triple quadrupole LC-MS instrument that is commonly used for clinical mass spectrometry.

168 To determine the performance of this clinically-adapted UTI diagnostics approach, we  
169 conducted a head-to-head performance evaluation of our LC-MS method versus results obtained  
170 via the traditional clinical microbiology approach<sup>12</sup>. This cohort consisted of 587 urine specimens  
171 submitted to Alberta Precision Laboratories (South Hub) over a 48-hour period. The demographics  
172 of these specimens have been described previously<sup>7</sup>. Briefly, these samples were taken from the  
173 greater Calgary metropolitan area where 74% of urine cultures are submitted from ambulatory out-  
174 patient visits, 18% from hospitalized patients, and 9% from nursing home residents. Females have  
175 a 6-fold higher incidence rate of UTIs than males in this population. Importantly, Alberta follows

176 the “Choosing Wisely Canada” guidelines wherein physicians are instructed to only submit urine  
177 cultures from symptomatic patients<sup>13</sup>. This head-to-head trial confirmed our previous results: urine  
178 agmatine levels correctly predicted *Enterobacterales* infections (Figure 3, AUC of 0.96; CI of 0.94  
179 – 0.98). Moreover, at the previously determined agmatine threshold of 174 nM, LC-MS diagnostics  
180 had a 95% sensitivity and 86% specificity for predicting *Enterobacterales* infections (Figure 3,  
181 Supporting Dataset 5). As expected, our culture-negative samples, those classified as being of  
182 doubtful clinical significance (DCS;  $<10^7$  CFU/L), and a small number of urine samples (<5%)  
183 containing non-*Enterobacterales* microbes all had agmatine levels below the limit of detection.

184

#### 185 *Clinical Cohort 2*

186 One limitation of our original targeted method is that it was specific to agmatine and thus could  
187 not be expanded to the analysis of other urinary metabolites, including creatinine, a standard marker  
188 of urinary dilution<sup>14,15</sup>. To address this limitation, we developed a “dilute and shoot” sample  
189 preparation workflow coupled with a 3.2-minute LC-MS targeted assay for agmatine, N6-  
190 methyladenine, and creatinine. To enable accurate quantification of agmatine/N6-methyladenine  
191 and creatinine, which are present at substantially different concentrations in urine (nM versus mM),  
192 we used a higher dilution (1:200 final) than in the previous trial. Using this assay, we analyzed  
193 1,042 urine specimens from suspect UTI cases. In this cohort, we again showed that urinary  
194 agmatine concentrations over 174 nM is an accurate predictor of *Enterobacterales* infections (93%  
195 sensitivity; 90% specificity; PPV, 0.67; NPV, 0.98; Figure 4, Supporting Dataset 6). Moreover, we  
196 showed that creatinine normalization had a slight negative impact on the performance of the assay  
197 (AUC of 0.95, CI 0.93-0.97; versus 0.92, CI 0.89-0.95; for agmatine alone versus creatinine-  
198 normalized agmatine levels, respectively; Figure 4, Supplemental Dataset 6). N6-methyladenine  
199 levels were also found to be predictive of UTIs (AUC of 0.71, CI 0.69 – 0.74; inclusive of all  
200 species; Supplemental Dataset 6). As expected, the performance of N6-methyladenine was



201 improved when analyses were restricted to the three known N6-methyladenine producing species  
202 (AUC, 0.89; CI, 0.75 - 1.0; Supporting Dataset 6, Supplementary Figure 2). In this restricted sub-  
203 cohort, a N6-methyladenine concentration of 217 nM had a sensitivity of 0.78 and specificity of  
204 0.79 for differentiating infections with *S. aureus*, *S. saprophyticus*, and *A. urinae* versus infections  
205 with all other species and negative specimens (Supplementary Figure 2, Supporting Dataset 6). We  
206 also tested the performance of a composite model using both agmatine and N6-methyladenine  
207 levels to predict infections. This combined model performed slightly worse than the agmatine-only  
208 model as a generalized tool for detecting UTIs (inclusive of all species, AUC of 0.85 versus 0.78  
209 for the composite versus agmatine-only models, respectively; Supporting Dataset 6).

210

## 211 Discussion

212 UTIs are one of the most common bacterial infections and are responsible for over eight  
213 million healthcare visits per year in the U.S. alone<sup>16,17</sup>. As a result, urine cultures are one of the  
214 most common tests performed by microbiology reference labs (24–40% of all cultures analyzed)<sup>18</sup>.  
215 The current diagnostic workflow used to process these samples follows a multi-day procedure that  
216 includes: streaking urines on agar plates, incubation for 18 hours, colony counting, microbial  
217 identification via MALDI-TOF mass spectrometry, and antibiotic susceptibility testing<sup>12</sup>. This long  
218 diagnostic workflow (24–48 hours) encourages clinicians to prescribe antibiotics before lab results  
219 are available. Given that up to 70% of suspected UTI cases collected by clinical testing facilities  
220 are ultimately found to be culture negative, the current empiric antimicrobial prescribing practice  
221 leads to overprescribing and may contribute to the spread of antimicrobial resistance<sup>19–21</sup>.  
222 Therefore, rapid diagnostic tools that can quickly identify patients with UTIs could enable more  
223 precise antimicrobial prescribing practices<sup>22–24</sup>.

224 Herein, we used untargeted metabolomics to identify native biomarkers present in uncultured  
225 urine that robustly differentiate between culture negative and culture positive patients. Using these

226 untargeted data, we identified two predictive metabolites (agmatine and N6-methyladenine) that  
227 are elevated in uncultured urine from patients who were later confirmed to have UTIs. We show  
228 that these biomarkers are produced by UTI pathogens when they are cultured in urine and that an  
229 agmatine concentration of 174 nM and N6-methyladenine concentration of 217 nM in urine  
230 corresponds with the clinical definition of bacteriuria ( $>10^7$  CFU/L)<sup>8</sup>. We developed a clinical LC-  
231 MS workflow to detect these molecules and demonstrated that these biomarkers are robust  
232 predictors of UTIs in two independent cohorts consisting of 1,629 clinical specimens in total (AUC  
233  $> 0.95$  and  $0.89$  for 13 *Enterobacterales* and 3 non-*Enterobacterales* species, respectively).  
234 Collectively, these data show that metabolite levels present in uncultured urine can be used to  
235 accurately reproduce the results generated by traditional urine culture and, therefore, could  
236 potentially enable novel rapid UTI testing approaches.

237         The multiple independent trials we conducted over the course of this study provide some  
238 insights into leveraging metabolite biomarkers of UTIs. Firstly, our creatinine normalization study  
239 showed that correcting metabolite levels to account for variability in urinary dilution does not  
240 improve their diagnostic performance – if anything these corrections make things worse (Figure 4;  
241 Supporting Dataset 6). This observation is consistent with our microbial culturing experiments,  
242 which showed that agmatine and N6-methyladenine are normal microbial catabolites produced  
243 when UTI pathogens are grown in urine. Thus, if agmatine and N6-methyladenine levels in patient  
244 samples primarily result from microbial metabolism within the urinary tract, we would expect both  
245 the biomarker levels and planktonic bacterial density in the urine (in CFU/L) to be diluted in  
246 parallel. Given that the clinical definition of bacteriuria is based on bacterial density<sup>8</sup> it is  
247 unsurprising that the microbially-produced catabolites we identified were most diagnostically  
248 robust when their levels were not corrected for urinary dilution. This observation has practical  
249 implications: quantifying the abundant creatinine necessitated a higher dilution than is necessary  
250 for quantifying the low-abundant agmatine and N6-methyladenine. This over-dilution diminished

251 the performance of our target markers in our final clinical cohort, as their signals were closer to the  
252 LC-MS noise threshold. Thus, omitting creatinine normalization improves performance of our  
253 assay.

254 Another practical observation from our final clinical cohort is that a mixed agmatine/N6-  
255 methyladenine model for predicting infection performed slightly worse than an agmatine only  
256 model (all cause UTI; mixed AUC 0.78, 0.74-0.81; agmatine only AUC 0.85, 0.82-0.88; Supporting  
257 Dataset 6). The reason for this is that only 9 out of the 1,042 urine specimens (9 out of 277 positive  
258 samples; 3.2%) in the final cohort were from infections with N6-methyladenine-producing  
259 organisms. This prevalence is consistent with previous studies in the same region (3.2% vs 2.1%)<sup>7</sup>.  
260 Thus, screening samples via N6-methyladenine levels added false discovery, but minimal  
261 additional sensitivity to the assay. This is a common problem in screening for rare events<sup>25</sup> and  
262 suggests that an agmatine-only screening approach might be preferable.

263 One important consideration about the generalizability of our findings is that the mix of species  
264 observed in clinical specimens will have a direct impact on the clinical performance of our  
265 biomarker-based diagnostic approach. The proportions of species we observed are largely  
266 consistent with those reported elsewhere with the exception of *S. saprophyticus* (an N6-  
267 methyladenine-producer), which was underrepresented relative to the North American average (1%  
268 vs 5%)<sup>26,27</sup>. Therefore, N6-methyladenine could potentially be of greater diagnostic value in other  
269 health jurisdictions – especially in jurisdictions with a greater proportion of out-patient cases.

270 The robust performance of agmatine as a diagnostic marker for *Enterobacteriales* infections  
271 across four separate cohorts suggests that this metabolite is a good candidate for clinical  
272 applications. As an LC-MS assay, agmatine screening could be used to rapidly identify patients  
273 with clinically significant bacteriuria. This screening approach is 18 hours faster than the traditional  
274 urine culture workflow and could accommodate thousands of analyses per day<sup>28</sup>. Alternatively,  
275 agmatine screening for UTIs could also be enabled via point-of-care testing tools, such as lateral

276 flow assays, which could be made possible via existing commercial antibodies for agmatine<sup>29</sup>. If  
277 such a point-of-care tool were made, it would complement existing dipstick-style UTI screening  
278 tests (i.e. nitrate and leucocyte esterase)<sup>30</sup>. In this context, agmatine screening would be both  
279 favorable from a performance perspective (Supporting Dataset 7) and because the  
280 *Enterobacterales*-specific agmatine test could be used to help guide more precise prescribing  
281 decisions.

282 Although we demonstrate robust performance of our metabolomics-based UTI screening  
283 concept, there are some important limitations of this strategy that warrant discussion. Firstly, the  
284 biomarkers we identify here report bacteriuria (high levels of bacteria in the urine), not infection.  
285 This distinction is important as asymptomatic bacteriuria is common and does not necessarily  
286 warrant antimicrobial therapy<sup>31</sup>. Thus, agmatine/N6-methaladenine screening would need to be  
287 paired with symptomatic evaluation by a clinician to enable UTI diagnosis (i.e. following existing  
288 practice). Secondly, the gold-standard diagnostic workflow involves both species-level  
289 identification of the pathogen and empiric antimicrobial susceptibility testing, neither of which is  
290 possible with our screening approach alone. However, most UTIs are treated without supporting  
291 lab data. Therefore, we envision agmatine/N6-methaladenine screening as a tool to improve  
292 empiric prescribing practices rather than as a replacement for culture-based diagnostics. Thirdly,  
293 the biomarkers we report here have clinically significant blind spots, especially in the context of  
294 UTIs from hospitalised patients. New biomarkers covering *Candida*, *Enterococcus*, *Pseudomonas*,  
295 and group B *Streptococcus* must be identified if our proposed metabolism-based UTI screening  
296 concept is to be applied to hospitalized patients. Despite these limitations, the agmatine/N6-  
297 methaladenine screening approach we introduce here is robust, reproducible over multiple  
298 independent clinical cohorts, and could add significant value as a point-of-care or patient-near tool  
299 to enable more precise empiric prescribing decisions for uncomplicated UTIs.

300

301

## 302 **Methods**

### 303 *Experimental design*

304 Untargeted analysis for biomarker discovery was performed directly on patient urine samples  
305 (77 culture positive, 33 culture negative) using a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™  
306 Mass Spectrometer. Putative biomarkers were identified using MS/MS analysis and matched to  
307 standards using fragmentation spectra and retention times. To identify agmatine thresholds that  
308 differentiate culture positive ( $\geq 10^7$  CFU/L; n=240) versus culture negative urines ( $< 10^7$  CFU/L;  
309 n=279), patient urines were spiked with a known concentration of labeled [U-<sup>13</sup>C]agmatine,  
310 purified using solid phase extraction (SPE), and analyzed on the TSQ Quantum™ Access MAX  
311 Triple Quadrupole Mass Spectrometer. Agmatine concentrations were quantified based on the  
312 signal ratio between isotope-labeled and native species. Quantitative analyses of N6-methyladenine  
313 were performed directly on patient urine samples (71 culture positive non-*Enterobacteriales*, 24  
314 culture negative) using external standards following analysis via the Q Exactive™ HF platform. To  
315 demonstrate that agmatine and N6-methyladenine originate from microbial metabolism, *E. coli* and  
316 *S. aureus* were incubated in sterilized urine and production of biomarkers was monitored. Similarly,  
317 to demonstrate that agmatine concentrations are proportional to microbial load, Mueller Hinton  
318 Medium was seeded with varying concentrations of *E. coli* ( $10^3$ - $10^8$  CFU/mL) and agmatine levels  
319 were measured following a 6-hour incubation period. Inhibition of agmatine production by boric  
320 acid was also monitored in filter sterilized urine seeded with *E. coli* during a 24-hour incubation  
321 period. Two clinical trials were performed to validate discovered biomarkers. The first clinical trial  
322 was performed using SPE purified urine samples (n=587) on the TSQ Quantum™. In the second  
323 clinical trial (dilute and shoot approach), methods were developed to quantify agmatine, N6-  
324 methyladenine, and creatinine directly in urine using a single injection. For these analyses, urine

325 from residual clinical urine samples (n=1,042) was analyzed after a 1:200 dilution (V:V in 50%  
326 methanol final) using the TSQ Altis™ triple quadrupole. The specific LC-MS methods for each  
327 experiment are described below.

#### 328 *Urine sample collection*

329 Mid-stream urine samples were collected from Alberta Precision Laboratories' (APL)  
330 standardized urine analysis workflow, consisting of samples submitted for urine culture from  
331 symptomatic ambulatory (74%), hospitalized (18%), and nursing home patients (9%) in the Calgary  
332 metropolitan area. Age demographics are divided as follows: 20/1,000 for ages <1; <20/1,000 for  
333 ages 1-59; 24/1,000 for ages 60-69; 32/1,000 for ages 70-79; 100/1,000 for ages 80-89; 851/1,000  
334 for ages >90. Incidence rates in females are 30/1,000 and males are 5/1,000. Samples were de-  
335 identified prior to transfer to the study team. In brief, urine was plated either manually with a loop  
336 or using automated equipment onto UriSelect™ Media (Bio-Rad, Canada) and incubated  
337 aerobically for 18 hours. Growth of bacteria was enumerated as per standard recommendations<sup>12</sup>  
338 and colonies present in significant quantities were speciated using the Vitek™ MS system  
339 (bioMérieux, Canada). Residual samples from this standard diagnostic lab workflow were fixed  
340 1:1 with 100% methanol within 48 hours post-receipt at APL, and then frozen at -80 °C. All samples  
341 were thawed, centrifuged at 14,800 × g, and diluted ten-fold further into 50% HPLC-grade  
342 methanol prior to LC-MS analysis. All samples were acquired under approval from Conjoint Health  
343 Research Ethics Board certificate REB19-0442.

#### 344 *Untargeted mass spectrometry*

345 Untargeted analysis of positive and negative urine samples was performed for UTI biomarker  
346 discovery and quantification of N6-methyladenine thresholds. Methods were adapted from  
347 previously published studies<sup>32-37</sup>. Briefly, metabolic analyses were performed on a Q Exactive™  
348 HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo-Fisher) coupled to a Vanquish™

349 UHPLC System (Thermo-Fisher). Chromatographic separation of metabolites was performed on  
350 Synchronis HILIC UHPLC column (2.1mm x 100 mm x 1.7  $\mu$ m, Thermo-Fisher) at a flow rate of  
351 600  $\mu$ L/min using a binary solvent system: solvent A, 20 mM ammonium formate pH 3.0 in mass  
352 spectrometry grade H<sub>2</sub>O and solvent B, mass spectrometry grade acetonitrile with 0.1% formic acid  
353 (%v/v). For initial biomarker discovery experiments, the following 15-minute gradient was used:  
354 0–2 min, 100% B; 2–7 min, 100–80% B; 7–10 min, 80–5% B; 10–12 min, 5% B; 12–13 min, 5–  
355 100% B; 13–15 min, 100% B. The mass spectrometer was run in positive and negative full scan  
356 mode at a resolution of 240,000 scanning from 50–750 m/z. Metabolite data were analyzed by EI-  
357 MAVEN software package<sup>38,39</sup>. Metabolites were identified by matching observed m/z signals (+/-  
358 10 ppm) and chromatographic retention times to those observed from a commercial metabolite  
359 library of standards (MSMLS; Sigma-Aldrich). Assignments were verified on the Thermo Fisher  
360 Q Exactive™ HF platform via MS/MS fragmentation analysis and co-elution of standards with the  
361 identified signals from urine.

#### 362 *Targeted mass spectrometry*

363 Targeted mass spectrometry analysis for validation of agmatine as a UTI biomarker and clinical  
364 trial 1 was performed on a TSQ Quantum™ Access MAX (Thermo Scientific). For quantitative  
365 analyses the following transitions were monitored using a fixed collision energy of 15 eV: <sup>12</sup>C  
366 agmatine, 131.2→72.4 m/z; [U-<sup>13</sup>C]agmatine, 136.2→76.4 m/z in positive ionization mode. The  
367 same HPLC column and buffers were used as described above, with the following modified 6-  
368 minute gradient: 0–0.5 min, 100% B; 0.5–2 min, 100–5% B; 2–3.5 min, 5–0% B; 3.5–4.5 min, 0%  
369 B; 4.5–5 min, 0–100% B; 5–6 min, 100% B. For targeted experiments using the TSQ Quantum™,  
370 electrospray ionization source conditions were as follows: spray voltage of 3000 V, sheath gas of  
371 25 (arbitrary units), auxiliary gas of 10 (arbitrary units), sweep gas of 0 (arbitrary units), capillary  
372 temperature of 275 °C, auxiliary gas temperature of 325 °C.

#### 373 *Dilute and shoot*

374 For clinical trial 2 (“dilute and shoot” approach), LC-MS/MS analysis was performed on a  
375 Vanquish™ UHPLC system, with an integrated Vanquish™ charger module (Thermo Scientific),  
376 coupled to a TSQ Altis™ triple quadrupole mass spectrometer (Thermo Scientific) equipped with  
377 an electrospray ionization (HESI-II) probe. The UHPLC-MS platform was controlled by an  
378 Xcalibur™ data system (Thermo Scientific). Chromatographic separation was achieved on a  
379 Synchronis™ HILIC column (50 X 2.1 mm, 1.7 μm, Thermo Fisher Scientific) using a binary  
380 solvent system composed of LC-MS grade H<sub>2</sub>O with 20 mM ammonium formate, pH3 (solvent A)  
381 and LC-MS grade acetonitrile with 0.1% (%v/v) formic acid (solvent B). The following 3.2 min  
382 gradient was used: 0–0.5 min, 95% B; 0.5–1.75 min, 95-30% B; 1.75–1.8 min, 30-5% B; 1.8–2.3  
383 min, 5% B; 2.3-2.4 min, 5-95% B; 2.4-3.2 min, 95% B. The flow rate was 1 mL min<sup>-1</sup> and the  
384 sample injection volume 2 μL. The auto sampler and charger were kept at 6 °C and the column at  
385 30 °C. For quantitative analyses the following transitions were monitored using the following  
386 polarities, collision energies and transitions: agmatine, positive, 16 eV, 131.0→97.1 m/z; N6-  
387 methyladenine, positive, 23 eV, 150.0→122.9 m/z; creatinine, positive, 13 eV, 114.1→86.1 m/z.  
388 Electrospray ionization source conditions were as follows: spray voltage of 3000 V (2500 V,  
389 negative mode), vaporizer temperature of 250 °C, sheath gas of 35 (arbitrary units), auxiliary gas  
390 flow of 15(arbitrary units) and sweep gas flow of 2 (arbitrary units), capillary temperature of 275  
391 °C.

#### 392 *Determination of agmatine threshold values using [U-<sup>13</sup>C]agmatine*

393 Targeted quantitative analysis was conducted to establish agmatine thresholds between culture  
394 positive and culture negative urine samples (Validation of agmatine as a UTI marker) and to assess  
395 performance thresholds (Clinical cohort 1). Quantitative analyses of agmatine in 519 urine samples  
396 was undertaken using a known concentration of a [U-<sup>13</sup>C]agmatine isotope as an internal standard  
397 in the urine sample (see [U-<sup>13</sup>C]agmatine standard biosynthesis and purification below). Prior to  
398 MS analysis, samples were purified using a solid phase extraction (SPE) 96-well HyperSep™ Silica



399 plate. Columns were equilibrated with methanol followed by water, then loaded with the sample of  
400 interest. Columns were then washed with methanol, water, methanol with 0.1% formic acid, water  
401 with 0.1% formic acid. The target analyte was eluted with water containing 2% formic acid. LC-  
402 MS analysis was performed using a TSQ Quantum™ Access MAX Triple Quadrupole Mass  
403 Spectrometer (Thermo Scientific). For the clinically-adapted blinded evaluation, clinical urine  
404 specimens were centrifuged and the supernatant was spiked with the [U-<sup>13</sup>C]agmatine isotope.  
405 These samples were analyzed directly on a TSQ Quantum™ Access MAX instrument.

406

#### 407 *[U-<sup>13</sup>C]agmatine standard biosynthesis and purification*

408 *Escherichia coli* (strain MG1665) was seeded into M9 minimal media containing 22.2 mM [U-  
409 <sup>13</sup>C]glucose, grown overnight, and was then seeded into fresh [U-<sup>13</sup>C]glucose-containing media.  
410 This culture was then incubated under agitation in a 37 °C, 5% CO<sub>2</sub> incubator. Glucose  
411 consumption was monitored using a blood glucose monitoring system (Bayer Contour Next). When  
412 glucose levels in the media reached 5 mM, the culture was centrifuged, the supernatant was  
413 retrieved, was adjusted to pH 7 with ammonium bicarbonate, and was steri-filtered. [U-  
414 <sup>13</sup>C]agmatine was isolated and purified using a solid phase extraction column (HyperSep™ Silica  
415 Cartridges, # 60108-712, Thermo Scientific), as described above and scaled accordingly to the  
416 column volume. The fraction was concentrated to 1/10<sup>th</sup> of its initial volume in a vacuum  
417 concentrator at 4 °C and labeled [U-<sup>13</sup>C]agmatine in the final sample was quantified by stable  
418 isotope dilution via LC-MS/MS using an unlabeled internal standard curve.

#### 419 *Validation of microbial metabolic capacity*

420 *E. coli* and *S. aureus* were inoculated in sterilized urine to verify that agmatine and N6-  
421 methyladenine originate from microbial metabolism. *In vitro* microbial samples were cultured from  
422 reference strains of bacteria (*E. coli*: MG1665, ATCC 25922, ESBL ATCC BAA-196; *S. aureus*:  
423 ATCC25923, ATCC 43300 (MRSA)). Briefly, cryogenic stocks were grown overnight in Mueller-

424 Hinton medium, then inoculated at  $10^5$  CFU/mL in sterilized urine and grown at 37 °C. *E. coli*  
425 cultures were spiked with [guanido- $^{15}\text{N}_2$ ]arginine (herein referred to as “[ $^{15}\text{N}_2$ ]arginine”) such that  
426 the urine contained an approximate 1:1  $^{12}\text{C}$  arginine to [ $^{15}\text{N}_2$ ]arginine ratio. The disappearance of  
427 [ $^{15}\text{N}_2$ ]arginine and appearance of [guanido- $^{15}\text{N}_2$ ]agmatine (herein referred to as “[ $^{15}\text{N}_2$ ]agmatine”)   
428 was monitored over five hours using LC-MS/MS. Similarly, the appearance of the N6-  
429 methyladenine signal was assessed in *S. aureus* cultures at 0, 4, 8, 10, and 12 hours with LC-MS.

430 To demonstrate that agmatine concentrations are proportional to microbial load, Muller Hinton  
431 Medium was seeded with varying concentrations of *E. coli* (ATCC 25922;  $10^3$ - $10^8$  CFU/mL) and  
432 agmatine levels were measured following a 6-hour incubation period using the Q Exactive™ HF  
433 platform. Inhibition of agmatine production by boric acid preservative, at concentrations used in  
434 BD Vacutainer Plus Tubes (2.63 mg/mL boric acid, 3.95 mg/mL sodium borate, 1.65 mg/mL  
435 sodium formate) was monitored in filter sterilized urine seeded with *E. coli* (three reference strains  
436 – MG1665, ATCC 25922, ATCC BAA-196 – and four clinical isolates) over a 24-hour period and  
437 analyzed on the Q Exactive™ HF platform.

#### 438 *Blinded performance evaluation of agmatine versus traditional urine analysis pipeline*

439 Mid-stream urine samples for the blinded head-to-head performance evaluation were collected  
440 from Alberta Precision Laboratories’ standardized urine analysis workflow (described above in  
441 *Urine Sample Collection*). These samples were stripped of diagnostic information and assigned a  
442 unique identifier prior to their transfer to the analytical team. Following analysis using a clinically  
443 adapted metabolomics platform, diagnostic data were un-masked and the results of the quantitative  
444 agmatine-based MS approach were scored against the clinical diagnostic laboratory calls, using  
445 174 nM as the threshold for UTI-positive samples.

446 Targeted quantitative assays were conducted in two independently blinded trials using slightly  
447 differing methods. In trial 1, targeted mass spectrometry was performed to quantify the levels of

448 agmatine in a blinded cohort of 587 urine specimens. This was done following the targeted mass  
449 spectrometry workflow described above using spiked in [U-<sup>13</sup>C]agmatine and SPE sample cleanup.

450 In trial 2, 1,042 urine specimens were analyzed using a simplified dilute and shoot targeted  
451 workflow that accurately captures the two target analytes as well as creatinine in a single injection.  
452 This approach negates the use of solid phase extraction, and instead, a 1/20 dilution of the sample  
453 was directly injected onto the MS following our chromatographic methods described above using  
454 a 3.2-minute gradient and external agmatine standard curves were used for quantification.

#### 455 *Data analysis and statistics*

456 Raw mass spectrometry files were converted into .mzXML files via MSConvertGUI  
457 (ProteoWizard Tools)<sup>40</sup>. All full scan MS analyses were conducted in MAVEN. MS/MS data were  
458 analyzed using Xcalibur 4.0.27.19 software (Thermo Scientific). Untargeted mass spectrometry  
459 data were grouped according to co-variance, co-retention and similarity to common  
460 adducts/fragments using previously published software developed in R Statistics<sup>41</sup>. Violin plots,  
461 ROC curves, and scatter plots were all generated in R Statistics using existing packages, (FUGU-  
462 MS, pROC, and vioPlot). A two-tail unequal variance Welch T-test was used to test differences in  
463 agmatine and N<sup>6</sup>-methyladenine levels in culture positive urine samples compared to negative  
464 controls. Alpha thresholds for significance were coerced for multiple hypothesis testing via  
465 Bonferroni correction

#### 466 **Data availability**

467 All data are available in the main text or the supplementary materials. Raw mass spectrometry data  
468 are available from the study team upon request.

469

470 **References**

- 471 1. Fernández-García, M., Rojo, D., Rey-Stolle, F., García, A. & Barbas, C. Metabolomic-  
472 Based Methods in Diagnosis and Monitoring Infection Progression. in *Metabolic*  
473 *Interaction in Infection* (eds. Silvestre, R. & Torrado, E.) 283–315 (Springer International  
474 Publishing, Cham, 2018). doi:10.1007/978-3-319-74932-7\_7.
- 475 2. Satink, H. P. W. M. *et al.* Microbial influences on urinary polyamine excretion. *Clin Chim*  
476 *Acta* **179**, 305–314 (1989).
- 477 3. Lussu, M. *et al.* 1H NMR spectroscopy-based metabolomics analysis for the diagnosis of  
478 symptomatic E. coli-associated urinary tract infection (UTI). *BMC Microbiol* **17**, 201  
479 (2017).
- 480 4. Bower, J. M. & Mulvey, M. A. Polyamine-mediated resistance of uropathogenic  
481 *Escherichia coli* to nitrosative stress. *J Bacteriol* **188**, 928–933 (2006).
- 482 5. Puebla-Barragan, S., Renaud, J., Sumarah, M. & Reid, G. Malodorous biogenic amines in  
483 *Escherichia coli*-caused urinary tract infections in women—a metabolomics approach. *Sci*  
484 *Rep* **10**, 9703 (2020).
- 485 6. Bouatra, S. *et al.* The Human Urine Metabolome. *PLoS One* **8**, e73076 (2013).
- 486 7. Laupland, K. B., Ross, T., Pitout, J. D. D., Church, D. L. & Gregson, D. B. Community-  
487 onset urinary tract infections: A population-based assessment. *Infection* **35**, 150–153  
488 (2007).
- 489 8. Alberta Precision Laboratories. *Change of Urine Colony Count Format*.  
490 [https://www.albertahealthservices.ca/assets/wf/lab/if-lab-hp-bulletin-change-of-urine-](https://www.albertahealthservices.ca/assets/wf/lab/if-lab-hp-bulletin-change-of-urine-colony-count-format.pdf)  
491 [colony-count-format.pdf](https://www.albertahealthservices.ca/assets/wf/lab/if-lab-hp-bulletin-change-of-urine-colony-count-format.pdf) (2021).
- 492 9. Lu, C.-D. Pathways and regulation of bacterial arginine metabolism and perspectives for  
493 obtaining arginine overproducing strains. *Applied Microbiology and Technology* **70**, 261–  
494 272 (2006).
- 495 10. Mohapatra, S. S. & Biondi, E. G. DNA Methylation in Prokaryotes: Regulation and  
496 Function. in *Cellular Ecophysiology of Microbe* (ed. Krell, T.) 1–21 (Springer, Cham,  
497 2017). doi:10.1007/978-3-319-20796-4\_23-1.
- 498 11. Adaway, J. E., Keevil, B. G. & Owen, L. J. Liquid chromatography tandem mass  
499 spectrometry in the clinical laboratory. *Ann Clin Biochem* **52**, 18–38 (2015).
- 500 12. Chan, W. W. Urine Cultures. in *Clinical Microbiology Procedures Handbook* (ed. Leber,  
501 A. L.) 3.12.1-3.12.33 (ASM Press, Washington, DC, 2016).  
502 doi:10.1128/9781555818814.CH3.12.
- 503 13. Leis, J. A. *et al.* Choosing Wisely Canada—Top five list in medical microbiology: An  
504 official position statement of the Association of Medical Microbiology and Infectious  
505 Disease (AMMI) Canada. *JAMMI* **3**, 61–70 (2018).
- 506 14. Arndt, T. Urine-creatinine concentration as a marker of urine dilution: reflections using a  
507 cohort of 45,000 samples. *Forensic Sci Int* **186**, 48–51 (2009).

- 508 15. Barr, D. B. *et al.* Urinary Creatinine Concentrations in the U.S. Population: Implications  
509 for Urinary Biologic Monitoring Measurements. *Environ Health Perspect* **113**, 192–200  
510 (2005).
- 511 16. Chu, C. M. & Lowder, J. L. Diagnosis and treatment of urinary tract infections across age  
512 groups. *Am J Obstet Gynecol* **219**, 40–51 (2018).
- 513 17. Schappert, S. M. & Rechtsteiner, E. A. Ambulatory medical care utilization estimates for  
514 2007. *Vital and Health Stats. 13* 1–38 (2011).
- 515 18. Wilson, M. L. & Gaido, L. Laboratory diagnosis of urinary tract infections in adult  
516 patients. *Clinical Infectious Diseases* **38**, 1150–1158 (2004).
- 517 19. Holmes, A. H. *et al.* Understanding the mechanisms and drivers of antimicrobial  
518 resistance. *The Lancet* **387**, 176–187 (2016).
- 519 20. Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of antibiotics.  
520 *Nat Rev Microbiol* **12**, 465–478 (2014).
- 521 21. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D. & Hay, A. D. Effect of antibiotic  
522 prescribing in primary care on antimicrobial resistance in individual patients: systematic  
523 review and meta-analysis. *BMJ* **340**, c2096 (2010).
- 524 22. O’Neill, J. Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics. *Review on*  
525 *Antimicrobial Resistance* (2015).
- 526 23. Waller, T. A., Pantin, S. A. L., Yenior, A. L. & Pujalte, G. G. A. Urinary Tract Infection  
527 Antibiotic Resistance in the United States. *Primary Care - Clinics in Office Practice* **45**,  
528 455–466 (2018).
- 529 24. Laxminarayan, R. *et al.* Antibiotic resistance—the need for global solutions. *Lancet Infect*  
530 *Dis* **13**, 1057–1098 (2013).
- 531 25. Maxim, L. D., Niebo, R. & Utell, M. J. Screening tests: A review with examples. *Inhal*  
532 *Toxicol* **26**, 811–828 (2014).
- 533 26. Kitto, K. & Colledge, E. Urinary Tract Infections in Adults. *Family & Community*  
534 *Medicine - University of Toronto* 1–2 Preprint at [http://thehub.utoronto.ca/family/wp-](http://thehub.utoronto.ca/family/wp-content/uploads/2018/03/Urinary-Tract-Infections-in-Adults.pdf)  
535 [content/uploads/2018/03/Urinary-Tract-Infections-in-Adults.pdf](http://thehub.utoronto.ca/family/wp-content/uploads/2018/03/Urinary-Tract-Infections-in-Adults.pdf) (2011).
- 536 27. Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract  
537 infections: Epidemiology, mechanisms of infection and treatment options. *Nat Rev*  
538 *Microbiol* **13**, 269–284 (2015).
- 539 28. Jannetto, P. J. & Fitzgerald, R. L. Effective use of mass spectrometry in the clinical  
540 laboratory. *Clin Chem* **62**, 92–98 (2016).
- 541 29. Huisman, H., Wynveen, P., Nichkova, M. & Kellermann, G. Novel ELISAs for screening  
542 of the biogenic amines GABA, glycine,  $\beta$ -phenylethylamine, agmatine, and taurine using  
543 one derivatization procedure of whole urine samples. *Anal Chem* **82**, 6526–6533 (2010).

- 544 30. Semeniuk, H. & Church, D. Evaluation of the Leukocyte Esterase and Nitrite Urine  
545 Dipstick Screening Tests for Detection of Bacteriuria in Women with Suspected  
546 Uncomplicated Urinary Tract Infections. *J Clin Microbiol* **37**, 3051–3052 (1999).
- 547 31. Nicolle, L. E. Asymptomatic bacteriuria: When to screen and when to treat. *Infect Dis*  
548 *Clin North Am* **17**, 367–394 (2003).
- 549 32. Dong, X. *et al.* Thermogenic hydrocarbon biodegradation by diverse depth-stratified  
550 microbial populations at a Scotian Basin cold seep. *Nat Commun* **11**, 5825 (2020).
- 551 33. Mager, L. F. *et al.* Microbiome-derived inosine modulates response to checkpoint  
552 inhibitor immunotherapy. *Science (1979)* **369**, 1481–1489 (2020).
- 553 34. Rydzak, T. *et al.* Metabolic preference assay for rapid diagnosis of bloodstream infections.  
554 *Nat Commun* **13**, 2332 (2022).
- 555 35. Groves, R. A. *et al.* Methods for Quantifying the Metabolic Boundary Fluxes of Cell  
556 Cultures in Large Cohorts by High-Resolution Hydrophilic Liquid Chromatography Mass  
557 Spectrometry. *Anal Chem* **94**, 8874–8882 (2022).
- 558 36. Mohammadi, M. *et al.* Microbial containment device: A platform for comprehensive  
559 analysis of microbial metabolism without sample preparation. *Front Microbiol* **13**, 1–13  
560 (2022).
- 561 37. Mapar, M., Rydzak, T., Groves, R. A. & Lewis, I. A. Biomarker enrichment medium: A  
562 defined medium for metabolomic analysis of microbial pathogens. *Front Microbiol* **13**,  
563 657158 (2022).
- 564 38. Clasquin, M. F., Melamud, E. & Rabinowitz, J. D. LC-MS Data Processing with  
565 MAVEN: A Metabolomic Analysis and Visualization Engine. *Curr Protoc Bioinformatics*  
566 **37**, 14.11.1-14.11.23 (2012).
- 567 39. Melamud, E., Vastag, L. & Rabinowitz, J. D. Metabolomic analysis and visualization  
568 engine for LC–MS data. *Anal Chem* **82**, 9818–9826 (2010).
- 569 40. Chambers, M. C. *et al.* A cross-platform toolkit for mass spectrometry and proteomics.  
570 *Nat Biotechnol* **30**, 918–920 (2012).
- 571 41. R Core Team. R: A Language and Environment for Statistical Computing. Preprint at  
572 <https://www.r-project.org/> (2019).

573

## 574 **Acknowledgments**

575

576 This work was supported by a Genomics Application Partnership Program award from Genome  
577 Canada (10019200), Genome Alberta (10021232), Canadian Institute of Health Research  
578 (10020019), and the 2017 Large Scale Applied Research Project competition. This work was made  
579 possible in part by a research collaboration agreement with Thermo Fisher Scientific. IAL was

580 supported by an Alberta Innovates Translational Health Chair (10010625). TR was supported by  
581 an Eyes High Postdoctoral Fellowship from the University of Calgary (10011121). S.D.W. was  
582 supported in part by an NSERC Undergraduate Summer Research Award. Metabolomics data were  
583 acquired at the Calgary Metabolomics Research Facility, which is part of the Alberta Centre for  
584 Advanced Diagnostics (ACAD; PrairiesCan RIE #22734) and is supported by the International  
585 Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986)

586

### 587 **Author Contributions**

588 S.D.W., C.C.Y.C., D.B.G., D.G.B., T.R., and I.A.L. designed and performed the experiments  
589 S.D.W., D.B.G., D.G.B., C.C.Y.C., R.A.G., D.B.G., R.A., and T.R. collected and interpreted mass  
590 spectrometry data. K.P., N.V.B., and I.A.L. interpreted results wrote the manuscript in consultation  
591 with all authors.


592

### 593 **Competing Interest Statement**

594 Drs. Lewis, Gregson and Mr. Groves are authors on a patent relating to the use of LC-MS for  
595 detecting urinary tract infections. No other competing interests declared.

596





597




598 **Figure 1. Discovery of agmatine and N6-methyladenine as UTI biomarkers.** (a) LC-MS data  
 599 were acquired from metabolites predictive of culture-positive (yellow points) and culture-  
 600 negative (purple points) urine samples. Potential UTI biomarkers were identified ( $m/z$  131.1289  
 601 and  $m/z$  150.0772 shown as example; see inset for chromatogram). (b) Predictive UTI biomarkers  
 602 were ranked according to receiver operating characteristic (ROC) curves. Signal 1 ( $m/z$  114.1025)  
 603 and signal 2 ( $m/z$  131.1289) were assigned to agmatine, and signal 3 ( $m/z$  150.0771) was assigned  
 604 to N6-methyladenine. (c) Agmatine and (d) N6-methyladenine assignments were verified by  
 605 tandem LC-MS/MS fragmentation patterns observed in a culture-positive urine sample (i, iv), an  
 606 analytical standard of the target molecule (ii; 250 nM, v; 50  $\mu$ M), and a standard added to a



607 culture-negative urine sample at the same concentration (iii, vi). Abbreviations: Agm, agmatine;

608 6-MA, N6-methyladenine; Neg, growth-negative urine; Pos, growth-positive urine.


609



611 **Figure 2. Microbial metabolite signals differentiate *Enterobacterales* and certain non-**  
612 ***Enterobacterales* positive urines from controls. (a)** Violin plot of agmatine concentrations in  
613 urine samples determined by spike-in of stable isotope-labeled internal standard following SPE  
614 (see inset). White dots indicate median values, thick black bars indicate interquartile ranges, and  
615 thin black lines indicate 3x interquartile hinge points. **(b)** Violin plot of N6-methyladenine signal  
616 intensities from a prospectively collected non-*Enterobacterales* cohort of patient urine samples.  
617 **(c)** Three *E. coli* strains grown in sterile urine spiked with [<sup>15</sup>N<sub>2</sub>]arginine for eight hours (top)  
618 were monitored for [<sup>15</sup>N<sub>2</sub>]agmatine production. Two *S. aureus* strains grown in sterile urine for 12  
619 hours (bottom) and were monitored for N6-methyladenine production. Abbreviations: Agm,  
620 agmatine; AUC, area under curve; CI, confidence interval; Thresh, threshold; PPV, positive  
621 predictive value; NPV, negative predictive value; DCS, doubtful clinical significance; Non-ENT,  
622 Non-*Enterobacterales*; ENT, *Enterobacterales*; STA, *Staphylococcus* species; AUR, *Aerococcus*  
623 *urinae*; Arg, arginine; 6MA, N6-methyladenine; GBS, Group B Streptococci.

624

625



626

627 **Figure 3. Blinded performance trial of clinically adapted metabolomics-based UTI**

628 **diagnostics. (a)** Agmatine concentrations in a blinded cohort of clinical urine samples. Categories

629 on x-axis represent calls from traditional microbiology analysis performed at a regional

630 diagnostic lab. **(b)** Receiver operator curve demonstrating the performance of agmatine as a

631 diagnostic marker for *Enterobacterales* in a blinded, prospective trial. Sensitivity and specificity

632 for 0.17 µM threshold is represented by the yellow dot. Abbreviations: NG, no growth; DCS,

633 doubtful clinical significance; Non-ENT, Non-*Enterobacterales*; ENT, *Enterobacterales*; Mix,

634 polymicrobial cultures containing at least one *Enterobacterales* member; AUC, area under curve;


635 CI, confidence interval; Thresh, threshold; PPV, positive predictive value; NPV, negative

636 predictive value.

637

638

639



640

641 **Figure 4. Creatinine normalized agmatine concentrations in a blinded cohort of urine**

642 **specimens. (a)** Violin plot of agmatine concentrations compared to creatinine normalized

643 agmatine concentrations. **(b)** Receiver operator curves demonstrating the equivalence between

644 detected agmatine levels and creatinine normalized agmatine levels. Sensitivity and specificity

645 calculated for 0.17  $\mu\text{M}$  threshold. Abbreviations: NG, no growth; DCS, doubtful clinical

646 significance; Non-ENT, Non-*Enterobacteriales*; ENT, *Enterobacteriales*; Mix, polymicrobial

647 cultures containing at least one *Enterobacteriales* member; AUC, area under curve.